CEO pay benchmark · $10B – $200B
Large-cap Biological Products, (No Diagnostic Substances) CEO salary
The median CEO compensation at large-cap companies in the biological products, (no diagnostic substances) industry is $17,302,304. That is 29% higher than the median across all biological products, (no diagnostic substances) companies in our benchmark.
Median CEO pay
$17.3M
Typical range
$11.2M–$24.4M
Companies
10
Average pay ratio
Not available
Vs. full industry
+29%
Size effect
How this group compares with the full industry
The same compensation measures are shown side by side, so the company-size difference is visible without mixing in another dataset.
| Measure | Large-cap | All Biological Products, (No Diagnostic Substances) |
|---|---|---|
| Companies | 10 | 17 |
| Median CEO pay | $17,302,304 | $13,448,935 |
| Average CEO pay | $18,447,050 | $15,494,357 |
| Middle 50% range | $11.2M–$24.4M | $8.2M–$23.2M |
| Average pay ratio | Not available | 24:1 |
Company appendix
Highest CEO pay in this peer group
Up to ten of the highest-paid CEOs in this benchmark, ordered by total annual compensation. Open any company for its full pay breakdown.
| Company | CEO | Total compensation | Market cap |
|---|---|---|---|
| EXELIXIS, INC.EXEL | Michael M. Morrissey | $33.2M | $14.5B |
| GILEAD SCIENCES, INC.GILD | Daniel P. O’Day | $28.4M | $162.9B |
| Amgen Inc.AMGN | Robert A. Bradway | $24.7M | $195.9B |
| BIOGEN INC.BIIB | Christopher A. Viehbacher | $23.6M | $31.7B |
| Moderna, Inc.MRNA | Stéphane Bancel | $19.9M | $31.2B |
| Revolution Medicines, Inc.RVMD | Mark A. Goldsmith | $14.7M | $36.6B |
| NEUROCRINE BIOSCIENCES INCNBIX | Kyle W. Gano | $13.4M | $17.5B |
| Krystal Biotech, Inc.KRYS | Krish S. Krishnan | $10.4M | $10.9B |
| TECHTECH | Kim Kelderman | $8.2M | $11.1B |
| ARGENX SEARGX | Tim Van Hauwermeiren | $7.8M | $57.1B |
Nearby peer groups